Adapt Pharma Inc. failed to convince the Federal Circuit to revive its four patents on the Narcan opioid overdose treatment felled by Teva Pharmaceuticals USA Inc.

The U.S. District Court for the District of New Jersey had invalidated the patents as obvious, paving the way for Teva and others to make generic versions of the nasal spray 15 years earlier than if the patents were allowed to expire.”

The Sterne, Kessler, Goldstein & Fox team representing Teva was led by J.C. Rozendaal, director (partner) and chair of the firm’s Trial & Appellate Group and includes fellow Directors: Paul Ainsworth, Michael Joffre, Adam LaRock, William Milliken, and Chandrika Vira.

To read the full article, please click the link below.

© 2022 The Bureau of National Affairs, Inc. All Rights Reserved